Interstitial Lung Disease — Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease
Citation(s)
A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome